AVTE RSI Chart
Last 7 days
4.1%
Last 30 days
-8.3%
Last 90 days
-1.3%
Trailing 12 Months
7.7%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | verwijs marinus | sold | -41,630 | 21.015 | -1,981 | chief technical officer |
May 01, 2024 | noyes timothy p | acquired | 21,400 | 2.14 | 10,000 | chief executive officer |
May 01, 2024 | noyes timothy p | sold | -230,946 | 20.3351 | -11,357 | chief executive officer |
Apr 17, 2024 | gillies hunter | sold | -89,521 | 22.3805 | -4,000 | chief medical officer |
Apr 17, 2024 | gillies hunter | acquired | 6,960 | 1.74 | 4,000 | chief medical officer |
Apr 17, 2024 | dake benjamin t | acquired | 14,665 | 2.14 | 6,853 | see remarks |
Apr 17, 2024 | dake benjamin t | sold | -153,327 | 22.3737 | -6,853 | see remarks |
Apr 16, 2024 | noyes timothy p | sold | -246,971 | 24.6971 | -10,000 | chief executive officer |
Apr 16, 2024 | noyes timothy p | acquired | 21,400 | 2.14 | 10,000 | chief executive officer |
Apr 10, 2024 | eldridge george a | acquired | 16,050 | 2.14 | 7,500 | see remarks |
Which funds bought or sold AVTE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Ikarian Capital, LLC | new | - | 10,880,700 | 10,880,700 | 1.19% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -14.05 | 36,487 | 333,076 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.91 | -8,402 | 33,237 | -% |
May 15, 2024 | ADAR1 Capital Management, LLC | new | - | 470,163 | 470,163 | 0.11% |
May 15, 2024 | Frazier Life Sciences Management, L.P. | unchanged | - | 8,361,780 | 35,627,900 | 1.50% |
May 15, 2024 | Shay Capital LLC | new | - | 727,067 | 727,067 | 0.11% |
May 15, 2024 | FRED ALGER MANAGEMENT, LLC | added | 20.04 | 469,373 | 1,294,870 | 0.01% |
May 15, 2024 | BAKER BROS. ADVISORS LP | unchanged | - | 11,662,800 | 49,692,900 | 0.62% |
May 15, 2024 | MORGAN STANLEY | reduced | -25.02 | -16,038 | 777,189 | -% |
May 15, 2024 | STATE STREET CORP | added | 7.46 | 1,957,260 | 6,800,690 | -% |
Unveiling Aerovate Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Aerovate Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Aerovate Therapeutics, Inc. News
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -16.2% | 107 | 127 | 141 | 156 | 124 | 135 | 148 | 156 | 167 | 175 | 184 | 62.00 | - |
Current Assets | -16.9% | 103 | 124 | 138 | 152 | 121 | 131 | 145 | 153 | 166 | 174 | 183 | 59.00 | 5.00 |
Cash Equivalents | -61.2% | 9.00 | 23.00 | 32.00 | 61.00 | 27.00 | 22.00 | 22.00 | 27.00 | 28.00 | 54.00 | 181 | 59.00 | 5.00 |
Net PPE | -9.7% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -11.4% | 16.00 | 18.00 | 15.00 | 14.00 | 11.00 | 9.00 | 9.00 | 5.00 | 5.00 | 3.00 | 4.00 | - | 2.00 |
Current Liabilities | -12.0% | 16.00 | 18.00 | 15.00 | 13.00 | 11.00 | 8.00 | 8.00 | 4.00 | 5.00 | 3.00 | 4.00 | 4.00 | 2.00 |
Shareholder's Equity | -16.9% | 91.00 | 109 | 126 | 142 | 113 | 127 | 139 | 151 | 162 | 172 | 180 | - | - |
Retained Earnings | -14.2% | -186 | -163 | -143 | -123 | -104 | -87.90 | -72.88 | -59.29 | -47.30 | -36.39 | -28.17 | -21.98 | -13.41 |
Additional Paid-In Capital | 1.8% | 278 | 273 | 269 | 266 | 218 | 215 | 213 | 211 | 210 | 209 | 208 | 0.00 | 0.00 |
Shares Outstanding | 0.4% | 28.00 | 28.00 | 28.00 | 28.00 | 25.00 | 25.00 | 24.00 | 24.00 | 24.00 | 24.00 | 8.00 | - | 0.00 |
Float | - | - | - | - | 232 | - | - | - | 157 | - | - | - | 185 | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -60.0% | -23,673 | -14,800 | -15,611 | -14,943 | -11,424 | -14,865 | -9,720 | -8,876 | -5,661 | -13,093 | -6,526 | -4,005 | -3,775 | - | - | - |
Share Based Compensation | 29.2% | 4,200 | 3,251 | 3,237 | 3,034 | 2,384 | 1,729 | 1,499 | 1,224 | 1,024 | 854 | 845 | 321 | 23.00 | - | - | - |
Cashflow From Investing | 56.4% | 8,833 | 5,648 | -13,130 | 3,983 | 15,375 | 14,486 | 4,645 | 8,194 | -20,399 | -113,338 | -56.00 | - | -40.00 | - | - | - |
Cashflow From Financing | 1.7% | 471 | 463 | 20.00 | 45,290 | 223 | 357 | 37.00 | - | - | -250 | 128,310 | 54,514 | 7,883 | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 20,080 | $ 13,488 |
General and administrative | 4,538 | 4,151 |
Total operating expenses | 24,618 | 17,639 |
Loss from operations | (24,618) | (17,639) |
Other income (expense): | ||
Interest income | 1,435 | 1,120 |
Other expense: | (3) | (1) |
Total other income | 1,432 | 1,119 |
Net loss | (23,186) | (16,520) |
Comprehensive loss: | ||
Net loss | (23,186) | (16,520) |
Other comprehensive loss: | ||
Unrealized (loss) gain on securities | (270) | 265 |
Comprehensive loss | $ (23,456) | $ (16,255) |
Net loss per share, basic | $ (0.83) | $ (0.67) |
Net loss per share, diluted | $ (0.83) | $ (0.67) |
Weighted-average shares of common stock outstanding, basic | 27,795,827 | 24,777,847 |
Weighted-average shares of common stock outstanding, diluted | 27,795,827 | 24,777,847 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 9,122 | $ 23,491 |
Short-term investments | 90,212 | 98,948 |
Prepaid expenses and other current assets | 3,905 | 1,793 |
Total current assets | 103,239 | 124,232 |
Property and equipment, net | 260 | 288 |
Operating lease right-of-use assets | 725 | 614 |
Other long-term assets | 2,597 | 2,284 |
Total assets | 106,821 | 127,418 |
Current liabilities: | ||
Accounts payable | 3,313 | 2,396 |
Accrued and other current liabilities | 11,760 | 14,821 |
Operating lease liabilities | 445 | 420 |
Total current liabilities | 15,518 | 17,637 |
Operating lease liabilities, net of current portion | 329 | 255 |
Other liabilities | 70 | 70 |
Total liabilities | 15,917 | 17,962 |
Commitments and contingencies (Note 5) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | ||
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 27,898,761 and 27,762,703 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 3 | 3 |
Additional paid-in capital | 277,544 | 272,640 |
Accumulated other comprehensive (loss) income | (33) | 237 |
Accumulated deficit | (186,610) | (163,424) |
Total stockholders' equity | 90,904 | 109,456 |
Total liabilities and stockholders' equity | $ 106,821 | $ 127,418 |